Osteosarcoma is an aggressive form of bone cancer and affects the health in children and adolescents. Although conventional treatment improves the osteosarcoma survival, some patients have metastasis and drug resistance, leading to a worse prognosis. Therefore, it is necessary to explore the molecular mechanism of osteosarcoma occurrence and progression, which could discover the novel treatment for osteosarcoma. Long noncoding RNAs (lncRNAs) have been reported to regulate osteosarcoma occurrence and malignant progression. LncRNA HOXA-AS3 facilitates the tumorigenesis and progression in a variety of human cancers. However, the underlying mechanism of lncRNA HOXA-AS3-induced oncogenesis is poorly determined in osteosarcoma. To address this point, we utilized several cellular biological strategies and molecular approaches to explore the biological functions and mechanisms of lncRNA HOXA-AS3 in osteosarcoma cells. We found that lncRNA HOXA-AS3 facilitates cell proliferation and invasion via targeting miR-218-5p/FOXP1 axis in osteosarcoma. In conclusion, lncRNA HOXA-AS3 could be a promising target for osteosarcoma treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254915 | PMC |
| http://dx.doi.org/10.1038/s41598-024-67596-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heterogeneous Transcriptional Landscapes in Human Sporadic Parathyroid Gland Tumors.
Int J Mol Sci
October 2024
Bone Metabolism Diseases and Diabetes Unit, IRCCS Istituto Auxologico Italiano, 20145 Milan, Italy.
Article Synopsis
- Key molecules in parathyroid tumors have altered expression due to gene mutations, loss of heterozygosity, and abnormal methylation patterns, impacting tumorigenesis in sporadic parathyroid adenomas (PAds).
- An analysis of 32 fresh PAd samples revealed two main clusters (C1 and C2), with C2 containing two subgroups (C2A and C2B) that show distinct gene expression patterns and clinical features, particularly in relation to the severity of primary hyperparathyroidism (PHPT).
- The C2A subgroup, marked by loss of TP73 and increased expression of specific lncRNAs, is associated with more severe PHPT, while the C2B subgroup features general down
Osteosarcoma is an aggressive form of bone cancer and affects the health in children and adolescents. Although conventional treatment improves the osteosarcoma survival, some patients have metastasis and drug resistance, leading to a worse prognosis. Therefore, it is necessary to explore the molecular mechanism of osteosarcoma occurrence and progression, which could discover the novel treatment for osteosarcoma.
View Article and Find Full Text PDFTumour-regulatory role of long non-coding RNA HOXA-AS3.
Prog Biophys Mol Biol
July 2024
China-ASEAN College of Marine Sciences, Xiamen University Malaysia, 43900 Sepang, Selangor, Malaysia. Electronic address:
Article Synopsis
- Dysregulation of a special type of RNA called HOXA-AS3 can lead to different kinds of cancer, and it may help to understand how tumors grow and spread.
- HOXA-AS3 interacts with some proteins and other small RNA molecules, which can affect important cellular activities that are linked to cancer progression.
- Although researching HOXA-AS3 could help in diagnosing and treating cancer, more studies are needed to really explore its role, and so far, there aren’t any approved treatments specifically targeting HOXA-AS3.
Long non-coding HOXA-AS3 contributes to osteosarcoma progression through the miR-1286/TEAD1 axis.
J Orthop Surg Res
September 2023
Department of Hand and Foot Surgery, Nanhua Hospital Affiliated to Nanhua University, Hengyang, 421002, China.
Long non-coding RNA (lncRNA) HOXA cluster antisense RNA 3 (HOXA-AS3) regulates the progression of several types of human malignancy. However, the role and potential mechanism of HOXA-AS3 in osteosarcoma (OS) remain unknown. In this study, upregulation of HOXA-AS3 was observed in OS tissues and cell lines and associated with poor clinical outcomes.
View Article and Find Full Text PDFThe prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
BMC Bioinformatics
July 2023
Department of Neurosurgery, General Hospital of Central Theatre Command of People's Liberation Arm, Wuhan, 430070, China.
Background: N6-methyladenosine (m6A) and 5-methylcytosine (m5C) are the main RNA methylation modifications involved in the oncogenesis of cancer. However, it remains obscure whether m6A/m5C-related long non-coding RNAs (lncRNAs) affect the development and progression of low grade gliomas (LGG).
Methods: We summarized 926 LGG tumor samples with RNA-seq data and clinical information from The Cancer Genome Atlas and Chinese Glioma Genome Atlas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!